Supernus Pharmaceuticals (SUPN) Launches Trokendi XR in the United States
9/5/2013 9:59:27 AM
ROCKVILLE, Md., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that Trokendi XR™ is now available to patients in the United States. Trokendi XR is a novel once-daily extended release formulation of topiramate for the treatment of epilepsy. The product has been shipped to major wholesalers in the market, and the Company's sales force is promoting the product to physicians.
Help employers find you! Check out all the jobs and post your resume.